NIVOLUMAB-ADJUVANT THERAPY FOR RESECTED STAGE III-IV MELANOMA: A COST-EFFECTIVENESS ANALYSIS FOR SPAIN

被引：0
|
作者：
Presa, M. [1 ]
Soria, A. [2 ]
Oyaguez, I [3 ]
Espinosa, E. [4 ]
Echave, M. [3 ]
Berrocal, A. [5 ]
Manzano, J. L. [6 ]
Suarez Rodriguez, J. [7 ]
Polanco Sanchez, C. [7 ]
机构：
[1] Pharmacoecon & Outcomes Res Iberia PORIB, Madrid, Spain
[2] Hosp Univ Ramon & Cajal, Madrid, Spain
[3] Pharmacoecon & Outcomes Res Iberia PORIB, Pozuelo De Alarcon, Spain
[4] Hosp Univ La Paz, Madrid, Spain
[5] Hosp Gen Univ Valencia, Valencia, Spain
[6] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain
[7] Bristol Myers Squibb Co, Madrid, Spain
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN108
引用
收藏
页码：S457 / S457
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients
    Saam A. Mojtahed
    Nicole R. Boyer
    Saieesh A. Rao
    Thomas F. Gajewski
    Jennifer Tseng
    Kiran K. Turaga
    [J]. Annals of Surgical Oncology, 2021, 28 : 9039 - 9047
  • [2] Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients
    Mojtahed, Saam A.
    Boyer, Nicole R.
    Rao, Saieesh A.
    Gajewski, Thomas F.
    Tseng, Jennifer
    Turaga, Kiran K.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (13) : 9039 - 9047
  • [3] Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
    Weber, J.
    Mandala, M.
    Del Vecchio, M.
    Gogas, H. J.
    Arance, A. M.
    Cowey, C. L.
    Dalle, S.
    Schenker, M.
    Chiarion-Sileni, V.
    Marquez-Rodas, I.
    Grob, J-J.
    Butler, M. O.
    Middleton, M. R.
    Maio, M.
    Atkinson, V.
    Queirolo, P.
    Gonzalez, R.
    Kudchadkar, R. R.
    Smylie, M.
    Meyer, N.
    Mortier, L.
    Atkins, M. B.
    Long, G. V.
    Bhatia, S.
    Lebbe, C.
    Rutkowski, P.
    Yokota, K.
    Yamazaki, N.
    Kim, T. M.
    de Pril, V.
    Sabater, J.
    Qureshi, A.
    Larkin, J.
    Ascierto, P. A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (19): : 1824 - 1835
  • [4] INCORPORATING POSSIBILITY OF CURE INTO COST UTILITY ANALYSIS FOR NIVOLUMAB IN ADJUVANT TREATMENT OF RESECTED STAGE III/IV MELANOMA IN FRANCE
    Harris, G.
    Orsini, I
    Edmonson-Jones, M.
    Moshyk, A.
    Bregman, B.
    Vanderpuye-Orgle, J.
    Chowdhury, E.
    Gaudin, A. F.
    Kurt, M.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S101 - S101
  • [5] Adjuvant nivolumab plus ipilimumab for resected stage IV melanoma
    Sullivan, Ryan Joseph
    [J]. LANCET, 2020, 395 (10236): : 1524 - 1525
  • [6] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB AS ADJUVANT TREATMENT FOR RESECTED STAGE IIB/IIC MELANOMA IN GREECE
    Yfantopoulos, N.
    Spanoudi, F.
    Draganigos, A.
    Skroumpelos, A.
    Karokis, A.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S122 - S122
  • [7] Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)
    Patel, S.
    Othus, M.
    Prieto, V.
    Lowe, M.
    Buchbinder, E.
    Chen, Y.
    Hyngstrom, J.
    Lao, C. D.
    Truong, T-G.
    Chandra, S.
    Kendra, K.
    Devoe, C.
    Hedge, A.
    Mangla, A.
    Sharon, E.
    Korde, L.
    Moon, J.
    Sondak, V.
    Ribas, A.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1408 - S1408
  • [8] Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States
    Bensimon, Arielle G.
    Zhou, Zheng-Yi
    Jenkins, Madeline
    Song, Yan
    Gao, Wei
    Signorovitch, James
    Krepler, Clemens
    Liu, Frank Xiaoqing
    Wang, Jingshu
    Aguiar-Ibanez, Raquel
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (10) : 981 - 993
  • [9] Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States
    Shujing Zhang
    Arielle G. Bensimon
    Ruifeng Xu
    Ruixuan Jiang
    Alexandra Greatsinger
    Adina Zhang
    Mizuho Fukunaga-Kalabis
    Clemens Krepler
    [J]. Advances in Therapy, 2023, 40 : 3038 - 3055
  • [10] Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States
    Zhang, Shujing
    Bensimon, Arielle G.
    Xu, Ruifeng
    Jiang, Ruixuan
    Greatsinger, Alexandra
    Zhang, Adina
    Fukunaga-Kalabis, Mizuho
    Krepler, Clemens
    [J]. ADVANCES IN THERAPY, 2023, 40 (07) : 3038 - 3055
12345